# NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC

> **NCT07295262** · EARLY_PHASE1 · RECRUITING · sponsor: **West China Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Liver Cancer, Adult

## Interventions

- **DRUG:** ICG-Cisplatin Nanoprobe (NIR-II NanoM)
- **PROCEDURE:** Fluorescence-guided Hepatectomy

## Key facts

- **NCT ID:** NCT07295262
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07295262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07295262, "NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07295262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*